Chemed (NYSE:CHE) Issues FY 2026 Earnings Guidance

Chemed (NYSE:CHE) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 25.000-25.750 for the period, compared to the consensus estimate of 24.010. The company issued revenue guidance of -.

Chemed Stock Performance

Shares of CHE stock traded up $18.98 during trading hours on Wednesday, hitting $536.61. The company’s stock had a trading volume of 109,443 shares, compared to its average volume of 222,119. The stock has a market cap of $7.12 billion, a PE ratio of 29.36, a price-to-earnings-growth ratio of 1.88 and a beta of 0.52. Chemed has a 12-month low of $365.20 and a 12-month high of $551.68. The company has a 50 day moving average of $461.43 and a 200 day moving average of $434.63. The company has a current ratio of 0.85, a quick ratio of 0.83 and a debt-to-equity ratio of 0.11.

Chemed (NYSE:CHE) last announced its quarterly earnings results on Tuesday, July 28th. The company reported $6.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.60 by $0.46. The firm had revenue of $673.25 million for the quarter, compared to the consensus estimate of $665.04 million. Chemed had a net margin of 10.23% and a return on equity of 27.18%. The firm’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $4.27 earnings per share. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. On average, sell-side analysts forecast that Chemed will post 22.67 EPS for the current fiscal year.

Chemed Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 16th. Investors of record on Thursday, May 28th were issued a $0.60 dividend. The ex-dividend date of this dividend was Thursday, May 28th. This represents a $2.40 annualized dividend and a yield of 0.4%. Chemed’s dividend payout ratio (DPR) is 13.08%.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Royal Bank Of Canada lifted their price target on Chemed from $422.00 to $436.00 and gave the company a “sector perform” rating in a report on Monday, April 27th. Weiss Ratings raised shares of Chemed from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, July 17th. Zacks Research raised Chemed from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Bank of America reissued a “neutral” rating on shares of Chemed in a research report on Wednesday. Finally, Wall Street Zen downgraded shares of Chemed from a “buy” rating to a “hold” rating in a research report on Monday, June 8th. One equities research analyst has rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $480.25.

Insider Transactions at Chemed

In other news, CEO Kevin J. Mcnamara sold 2,000 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $421.13, for a total value of $842,260.00. Following the sale, the chief executive officer owned 90,219 shares in the company, valued at approximately $37,993,927.47. This represents a 2.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Andrea R. Lindell sold 1,347 shares of the stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $447.33, for a total transaction of $602,553.51. Following the transaction, the director directly owned 4,578 shares in the company, valued at $2,047,876.74. The trade was a 22.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 3.33% of the company’s stock.

Institutional Trading of Chemed

Large investors have recently added to or reduced their stakes in the business. Los Angeles Capital Management LLC bought a new stake in shares of Chemed in the 4th quarter worth approximately $26,000. Global Retirement Partners LLC lifted its position in shares of Chemed by 200.0% during the 4th quarter. Global Retirement Partners LLC now owns 87 shares of the company’s stock worth $37,000 after buying an additional 58 shares during the period. Geneos Wealth Management Inc. grew its position in Chemed by 330.4% in the first quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock valued at $61,000 after acquiring an additional 76 shares during the period. Employees Retirement System of Texas acquired a new stake in shares of Chemed during the 3rd quarter worth about $64,000. Finally, Caitong International Asset Management Co. Ltd grew its stake in Chemed by 5,333.3% during the third quarter. Caitong International Asset Management Co. Ltd now owns 163 shares of the company’s stock worth $73,000 after buying an additional 160 shares during the last quarter. 95.85% of the stock is currently owned by institutional investors and hedge funds.

About Chemed

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.